Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2539 - Evaluation of Niraparib 200 mg/d as Maintenance Therapy in Recurrent Ovarian Cancer and Associated Thrombocytopenia in a Real-World US Setting


29 Sep 2019


Poster Display session 2


Premal Thaker


Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250


P. Thaker1, K. Travers2, C. Karki3, R.P. Patel3, C. Krebsbach4, B. Harrow2, S.N. Westin5

Author affiliations

  • 1 Gynecologic Oncology, Washington University, MO 63110 - Saint Louis/US
  • 2 Health Economics And Outcomes Research, TESARO: A GSK Company, 02451 - Waltham/US
  • 3 Health Economics And Outcomes Research, Ipsos Insights LLC, 10010 - New York/US
  • 4 Health Economics And Outcomes Research, Ipsos Insights LLC, New York/US
  • 5 Department Of Gynecologic Oncology And Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2539


Niraparib, a poly(ADP-ribose) polymerase inhibitor approved in 2017 by the US FDA (300 mg/d), has proven to be efficacious as maintenance therapy in patients (pts) with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (ROC) who are in complete or partial response (PR) to platinum-based chemotherapy (CT), with dose modification recommended to manage adverse reactions. This study assessed the rates of thrombocytopenia (TCP) among ROC pts who initiated niraparib 200 mg/d in a real-world US setting.


In July 2018, we recruited experienced (practicing ≥5 years) oncologists (N = 107), who were directly involved in treatment decisions, to complete an online survey and chart review (minimum of 1 and maximum of 2 charts) of adult pts (N = 150) with ROC who initiated niraparib 200 mg/d within 12 weeks of CT and had ≥3 months of follow-up. Data on pt demographics, disease history, comorbidities, biomarker status (BRCA and homologous recombination deficiency [HRD]), treatment use, and platelet counts (PC) were collected. Data were analyzed using descriptive statistics.


About 56% and 44% of pts received 1 and ≥2 lines of CT, respectively, and 55% had a PR to platinum-based CT immediately before niraparib initiation. Pts had stage III (39%) and stage IV (40%) ROC at diagnosis, with a mean disease duration of 1.3 years. BRCA and HRD testing occurred in 87 (58%) and 44 pts (29%), respectively. When asked the reason for initiating niraparib at 200 mg/d, 40% of oncologists reported starting all pts at 200 mg/d, 37% reported pt preference, 33% reported pt concern of toxicity, and 28% reported pt weight (median: 71 kg). Grade 3/4 TCP (per NCI CTCAE v4.03) occurred in 14% of pts post-initiation. Median time from niraparib initiation to the first PC test was 25.5 days. Of 77 pts (51%) with >1 PC test, median time from the first to the next test was 28 days.


In this chart review study, <1 in 5 pts had TCP (grade 3/4) and the median time from initiation to PC test was 25.5 days, both of which are lower than observed rates reported in the ENGOT-OV16/NOVA trial. Niraparib dose initiation at 200 mg/d may be beneficial in managing adverse reactions in pts with ROC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Tesaro: A GSK Company.


Tesaro: A GSK Company.


P. Thaker: Research funding: Merck, Tesaro; Grant for research / Consulting: Celsion Pharmaceuticals, AstraZeneca, Tesaro, Merck, AbbVie, Lovance, Unleash Oncolytics, Immunogen, Stryker. K. Travers: Full / Part-time employment: Tesaro: A GSK Company. C. Karki: Full / Part-time employment: Ipsos Insights, LLC. R.P. Patel: Full / Part-time employment: Ipsos Insights, LLC. C. Krebsbach: Full / Part-time employment: Ipsos Insights, LLC. B. Harrow: Full / Part-time employment: Tesaro: A GSK Company. S.N. Westin: Research Funding: ArQule; AstraZeneca; Bayer; Biomarin; Celgene (I); Clovis Oncology; Cotinga Pharmaceuticals; Critical Outcome Technologies; Karyopharm Therapeutics (I); Kite Pharma (I); Novartis; Roche/Genentech; Tesaro; Consulting / Advisory Role: AstraZeneca, BioAscent, Casdin Capital, Clovis Oncology, Genentech, Gerson Lehrman Group, Medivation, Medscape, Merck, Ovation Sciences, Pfizer, Roche, Tesaro, Vaniam Group, Vermillion, Watermark Research Partners.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.